Baxter presents VIVIA HD machine data at ERA/EDTA Print
Bloomberg: Baxter International Inc. (NYSE:BAX) today announced the presentation of clinical data supporting the safety and efficacy of the VIVIA haemodialysis (HD) system. Results from two studies conducted in a clinical setting showed acceptable clearance of uremic toxins and an overall safety profile similar to that associated with conventional HD devices. The VIVIA system, designed to deliver High Dose HD in the home, completed the CE marking process (market approval) in Europe, December 2013. The VIVIA haemodialysis system, which completed the CE marking process in Europe in December 2013, was designed to deliver High Dose HD therapy in the home.

...